PNParminder Nain

Parminder Nain

*This is an algorithmically generated author record based on publicly available information.

Parminder Nain has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study

    by Parminder Nain, Narendra Nayak, Mary C. Maj, Rohit Kumar Singh, Jaspreet Kaur, Yujin Jeong, Sabyasachi Maity, Reetuparna Nath, Robert H. Hilgers, Shreya Nauhria, et al.

    (1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer carbonate. (2) Objective: To evaluate the clinical efficacy of sevelamer carbonate in comparison to lanthanum carbonate as phosphate binders for the treatment of hyperphosphatemia in CKD patients. (3) Methods: A randomized control comparative clinical study was conducted for one year on 150 CKD patients associated with hyperphosphatemia, divided into two groups, i.e., Group 1 (n = 75) treated with sevelamer carbonate 800 mg thrice daily and Group 2 (n = 75) treated with lanthanum carbonate 500 mg thrice daily. The patients were assessed at the time of enrollment in the study, after three months and after six months from baseline for different parameters, i.e., complete blood count, liver function tests, renal function tests, electrolytes, and serum phosphate level. (4) Results: 150 CKD patients aged 51–60 participated in the study. The mean age of patients was 54 ± 4.6 years, and males (55.71%) were more common than females (44.29%). Hypertension was the common comorbidity in both groups with chronic kidney disease. After six months of treatment, the mean serum phosphate level was significantly decreased from 8.31 ± 0.09 mg/dL to 5.11 ± 0.18 (38%) in Group 1 and from 8.79 ± 0.28 mg/dl to 4.02 ± 0.12 (54%; p < 0.05) in Group 2, respectively. In both groups, no significant difference was found in other parameters such as parathyroid hormone, calcium, uric acid, LFT, RFT, CBC, etc. (5) Conclusion: Lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia as compared to sevelamer carbonate.


  • Evaluation of early Menopause symptoms in Post-Hysterectomy and Premature Ovarian insufficiency in women of reproductive age group

    by Vandana Rani, Jaspreet Kaur, Mamta Devi, Parminder Nain, Shaveta Garg, Prerna Sarup

    The present study was aimed at investigating early menopause symptoms in women of reproductive age with post-hysterectomy and premature ovarian insufficiency conditions. A total of 100 patients were included in the study after following inclusion and exclusion criteria. Data were collected by using a questionnaire (Menopause Rating Scale) based on the psychological, urogenital and somatic symptoms of the patients. The outcomes of study indicated that majority of women showed menopausal symptoms between 36 to 45 years of age, with a mean age of menopause was 42±3 years. While in premature menopause cases, the average age was 36 to 40 year with a mean age to attain it was 38±2 year. Further, the rate of psychological distress were highest in premature menopausal women as compared to normal menopausal women. The premature menopausal women experienced higher prevalence of somatic and urogenital symptoms as compared to normal menopausal women. Conclusively, premature menopausal women need to be considered in special category so that health care providers can plan strategies for them accordingly.


  • Vitamin D with Calcium Supplementation Managing Glycemic Control with HbA1c and Improve Quality of Life in Patients with Diabetes

    by Sanjana Mehta, Parminder Nain, Bimal K. Agrawal, Rajinder Pal Singh

    Objectives: This study evaluates the effect of vitamin D with calcium supplementation on glycemic control and quality of life (QoL) in patients with diabetes. Materials and Methods: A prospective, observational, open-label randomized, controlled study was conducted on 150 type-2 patients with diabetes. A total number of patients were divided into three groups (n= 50 in each group) i.e. group 1 (patient on oral hypoglycemic agents), group 2 (oral hypoglycemic agents with vitamin D 60.000 IU/week), and group 3 (oral hypoglycemic agents, vitamin D 60.000 IU/week along with daily calcium of 1.000 mg/day). Biochemical estimation of fasting/random blood glucose (RBG), hemoglobin A1c (HbA1c), serum insulin and patient's QoL were analyzed using modified diabetes QoL (MDQoL)-17 questionnaire after 12 weeks of treatment. Data were analyzed using a student t-test (paired t-test) Results: The majority of the patients were male (more than 50%) with an average age of 50 +/- 6 years having a diabetic history of more than 10 years and HbA1c level >10% in all three groups. After 12 weeks supplementation, the mean value of vitamin D was 25.73 +/- 6.2 ng/mL, 29.98 +/- 5.3 ng/mL and 62.71 +/- 7.8* ng/mL in groups 1, 2, and 3, respectively (p<0.05) compared to baseline. A change in the mean value of HbA1c, in group 2 (14.64 +/- 3.48 to 13.99 +/- 3.16%) and group 3 (14.05 +/- 2.65 to 12.04 +/- 2.21%) was also seen at the end of the study. Moreover, patients showed a positive effect of vitamin D with calcium in group 3 with increased MDQoL, 30% of patients were in more than 70 score range. Conclusion: The result of the study indicates that vitamin D supplementation with calcium significantly controlled or reduced HbA1c; fasting and RBG levels moreover improve QoL in type-2 patients with diabetes. It suggests that this combination can be considered a therapeutic supplement along with a primarily used anti-diabetic regimen.


  • Open Access

    Effectiveness of Empagliflozin With Vitamin D Supplementation in Peripheral Neuropathy in Type 2 Diabetic Patients

    by Sanjana Mehta, Parminder Nain, Bimal K. Agrawal, Rajinder P. Singh, Jaspreet Kaur, Sabyasachi Maity, Aniruddha Bhattarcharjee, Jagannadha Peela, Shreya Nauhria, Samal Nauhria

    Background: Neuropathy is the most prevalent broad-spectrum microvascular complication of diabetes. The present study aims to evaluate the effect of empagliflozin with vitamin D supplementation on diabetic peripheral neuropathy. Methods: A prospective, randomized, controlled study was conducted for six months including 150 type 2 diabetic patients, divided into three groups (n=50/group): Group 1, patients on oral hypoglycemic agents; Group 2, patients on empagliflozin and Group 3, patients on empagliflozin with vitamin D. Biochemical parameters were estimated for outcome measurements and patients’ neuropathic pain was analysed using Douleur Neuropathique 4 Questions, Neuropathic Pain Symptom Inventory and Ipswich Touch the toes test questionnaire. Data were analysed using a one-way analysis of variance. Results: Diabetic neuropathy in males was more prevalent (more than 50%) as compared to females in all three groups, with an average age of 50±6 years, along with a diabetic history of 15±4.5 years and a glycated hemoglobin A1C (HbA1C) level of >10%. The mean value of serum vitamin D level significantly increased by 64.7% (19±5 to 54±8 ng/mL; p<0.05). A remarkable decrease (by 17.4%) from baseline in the HbA1C level was observed after six months of treatment only in Group 3, whereas in other groups (1 and 2), there was a non-significant decrease in HbA1C levels when compared to baseline. Moreover, a significant improvement in neuropathic condition was seen only in Group 3. Conclusion: The results indicated that empagliflozin with vitamin D supplementation significantly controlled or reduced HbA1C and improved diabetic neuropathic symptoms in patients. It is suggested that this combination can be considered as the primary therapeutic approach for neuropathic complications in diabetic patients.


  • Anti-inflammatory effect of Sustained release granules of Aceclofenac in Gouty Arthritis Rat

    by Rajiv Kumar, Parminder Nain, Jaspreet Kaur, Ravi Kumar Dhawan

    Gout is most common painful clinical syndrome occurs due to hyperuricaemia (high serum uric acid level) and deposition of monosodium urate crystals in joints. In the current experimental study, the anti-inflammatory effect of sustained release granules of aceclofenac, was investigated on monosodium urate crystal-induced inflammation in rat. Monosodium urate is injected appropriately at a dose of 3 mg/kg body weight of a rat on right ankle to induce inflammation in joint like gouty arthritis. The percentage of joint swelling in positive control group was increased significantly (p<0.5) when compared with normal group after 1 hr, 12 hr and 24 hr with a single injection of MSU. Therapeutic effect of sustained released granules (OD) is similar to conventional released granules (BD) and possesses an anti-inflammatory effect, which could provide relief in gouty arthritis after administration of sustained release formulation of aceclofenac once in a day only. The current study clearly indicated that slow release granules of aceclofenac exerted a strong anti-inflammatory effect against gouty arthritis at standard dose once daily. It concluded that, when aceclofenac tablet is formulated with slow release granules it decreases the dosing frequency with same therapeutic effect.


  • Comparing the effect of insulin infusion alone and in combination of insulin infusion with salbutamol nebulization in treatment of hyperkalemia in diabetic and non-diabetic patients

    by Rohit Tiwari, Parmınder NAIN, Jasmine Kaur, Harbir Kaur Rao, Jaspreet Kaur

    Objective: To evaluate the clinical efficacy and comparison of lowering potassium level with insulin infusion alone and insulin infusion with salbutamol nebulization in diabetic and non-diabetic patients. Study Design: This interventional study was conducted in a tertiary care hospital, for a period of six month. A total of one hundred ninety patients with hyperkalemia were divided into two groups. Group-A (diabetic and non-diabetic patients) received salbutamol 20 mg TDS (nebulizer 5mg/2.5ml) administered over a period of 15 minutes with 10 units of regular insulin (diluted with 25% dextrose in non-diabetic only) administered over 30 minute TDS via infusion. Group-B (diabetic and non-diabetic patients) received 10 units of regular insulin (diluted with 25% dextrose in non-diabetic patients only) administered over 30 minute TDS via infusion. Potassium and glucose levels were measured in patients’ blood sample at 0, 6, 12 and 24 hours after the treatments. Results: In diabetic patients, the potassium level was decreased 30.09% and 20.49%, in group-A and group-B respectively 24 hours after the treatment. The result of blood glucose values indicates that, insulin infusion alone and insulin with salbutamol nebulizer were decrease upto 28.85 % and 40.78 % respectively after 6 hours in diabetic patients. Both the treatments were effective without any complication Renal, liver, cardiac & respiratory function test were recorded in a bihourly bases did not shows any significant changes after treatments. Conclusion: According to this study report, the combination of salbutamol nebulizer with insulin was more effective in the treatment of hyperkalemia in both diabetic and non-diabetic patients.

  • Open Access

    Potential Treatment of Psoriasis with Oral Spironolactone as TNF-Alpha Inhibitor – A Future Prospective Review

    by Sanjana Mehta, Parminder Nain, Jaspreet Sidana

    Dr. Sanjana Mehta, Research Scholar, Dr. Parminder Nain, Professor and Head, Dr. Jaspreet Kaur, Associate Professor Maharishi Markandeshwar College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana.

  • Open Access

    Mechanisms of Antidiabetic Activity of Methanolic Extract of Punica granatum Leaves in Nicotinamide/Streptozotocin-Induced Type 2 Diabetes in Rats

    by Shinu Pottathil, Parminder Nain, Mohamed A. Morsy, Jaspreet Kaur, Bandar E. Al-Dhubiab, Sandhya Jaiswal, Anroop B. Nair

    The current study aimed to establish the mechanisms of antidiabetic activity of methanolic extract of Punica granatum leaves (MEPGL) in nicotinamide/streptozotocin-induced type 2 diabetes in rats. Phytochemical screening, HPLC analysis, and acute toxicity study of MEPGL were carried out. Various concentrations of MEPGL (100, 200, 400, and 600 mg/kg) were administered orally to diabetic rats for 45 days on a daily basis. The antidiabetic effect of MEPGL was examined by measuring blood glucose, plasma insulin, and glycated hemoglobin (HbA1c) levels, as well as with an oral glucose tolerance test. The antioxidant effect of MEPGL was determined by analyzing hepatic and renal antioxidant markers, namely superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced glutathione (GSH), and lipid peroxidation. The other biochemical markers alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), urea, and creatinine, as well as total cholesterol, triglycerides, and high-density lipoprotein (HDL) were also studied. Type 2 diabetes significantly altered these parameters, while oral administration of the MEPGL significantly ameliorated them. Moreover, the pancreatic histopathological changes were attenuated with MEPGL treatment. In a nutshell, oral MEPGL administration in diabetic rats showed antidiabetic activity due to its antioxidant activity, most probably due to the gallic acid, ellagic acid, and apigenin found in MEPGL.